FI3798222T3 - Lorlatinibin vapaan emäksen kidemuoto - Google Patents
Lorlatinibin vapaan emäksen kidemuoto Download PDFInfo
- Publication number
- FI3798222T3 FI3798222T3 FIEP20202336.2T FI20202336T FI3798222T3 FI 3798222 T3 FI3798222 T3 FI 3798222T3 FI 20202336 T FI20202336 T FI 20202336T FI 3798222 T3 FI3798222 T3 FI 3798222T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- composition according
- free base
- weight
- ppm
- Prior art date
Links
- 239000012458 free base Substances 0.000 title claims 11
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title claims 11
- 229950001290 lorlatinib Drugs 0.000 title claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LEHJCMYPLJNJNF-UHFFFAOYSA-N 15-oxa-3,6,7,12-tetrazatricyclo[15.4.0.05,9]henicosa-1,3,5,7,9,11,13,16,18,20-decaene-8-carbonitrile Chemical compound O1C=CN=CC=C2C(C#N)=NN=C2C=NC=C2C=CC=CC2=C1 LEHJCMYPLJNJNF-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US201662352349P | 2016-06-20 | 2016-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3798222T3 true FI3798222T3 (fi) | 2023-11-28 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20202336.2T FI3798222T3 (fi) | 2015-07-31 | 2016-07-27 | Lorlatinibin vapaan emäksen kidemuoto |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (enExample) |
| EP (2) | EP3328867B9 (enExample) |
| JP (1) | JP6218253B2 (enExample) |
| KR (1) | KR102088188B1 (enExample) |
| CN (3) | CN116063322A (enExample) |
| AU (1) | AU2016304420B2 (enExample) |
| BR (1) | BR112017028604A2 (enExample) |
| CA (1) | CA2937257C (enExample) |
| CY (1) | CY1123689T1 (enExample) |
| DK (2) | DK3798222T3 (enExample) |
| ES (2) | ES2972010T3 (enExample) |
| FI (1) | FI3798222T3 (enExample) |
| HK (1) | HK1252845A1 (enExample) |
| HU (2) | HUE052790T2 (enExample) |
| MX (2) | MX395263B (enExample) |
| PL (2) | PL3328867T3 (enExample) |
| PT (2) | PT3328867T (enExample) |
| RU (1) | RU2018101363A (enExample) |
| SG (1) | SG10201913200XA (enExample) |
| SI (2) | SI3328867T1 (enExample) |
| TW (1) | TWI616449B (enExample) |
| WO (1) | WO2017021823A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017049383A1 (en) | 2015-09-24 | 2017-03-30 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| JP2019510774A (ja) | 2016-04-08 | 2019-04-18 | ファイザー・インク | ロルラチニブマレイン酸塩の結晶質形態 |
| CA3066499A1 (en) * | 2017-06-22 | 2018-12-27 | Cyclenium Pharma Inc. | Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same |
| FI3694863T3 (fi) * | 2017-10-10 | 2023-08-18 | Pfizer | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| US20220127262A1 (en) * | 2019-01-17 | 2022-04-28 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| KR20130105675A (ko) * | 2010-11-25 | 2013-09-25 | 라티오팜 게엠베하 | 아파티닙의 신규 염 및 다형 |
| WO2013132376A1 (en) * | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP3013835B1 (en) | 2013-06-28 | 2017-12-13 | Pfizer Inc | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| JP2019510774A (ja) | 2016-04-08 | 2019-04-18 | ファイザー・インク | ロルラチニブマレイン酸塩の結晶質形態 |
| FI3694863T3 (fi) | 2017-10-10 | 2023-08-18 | Pfizer | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
-
2016
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 MX MX2021002220A patent/MX395263B/es unknown
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 HK HK18112176.1A patent/HK1252845A1/zh unknown
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active Active
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/zh active Pending
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 MX MX2018001324A patent/MX382600B/es unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en not_active Ceased
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| MX386473B (es) | Formas solidas de un inhibidor de cdk4/6 selectivo | |
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| MY169142A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| ZA201900694B (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MX338150B (es) | Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2013013294A (es) | Inhibidores de tirosina-cinasas. | |
| MX2015005772A (es) | Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| RU2018101363A (ru) | Кристаллическая форма свободного основания лорлатиниба | |
| IN2012DN02577A (enExample) | ||
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| TR201821217T4 (tr) | Tirozin kinaz aktivitesinin inhibisyonu için yeni kaynaşmış pirimidin türevleri. | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| MX381000B (es) | Cristales de compuesto azabicíclico. | |
| MY199042A (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| MX373612B (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| MX2014011354A (es) | Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms. | |
| TN2014000433A1 (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2012002327A (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. |